This is the authors' abstract. We don't add key points for this paper.
Chronic myeloid leukemia (CML) is a myeloproliferative disorder treated with tyrosine kinase inhibitors (TKIs). While TKIs are effective in treating CML, their adverse effects can impact patient management. We present a case of an 83-year-old female diagnosed with CML in August 2024, initially treated with dasatinib but discontinued due to gastrointestinal toxicity. She was later started on imatinib in October 2024. One month later, she presented with progressive weakness and dyspnea, ultimately found to have a large pleural effusion requiring intervention. This case highlights the challenges in managing TKI-related adverse effects, particularly in elderly patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Alhaleem et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: